FDA Embraces Controversy Among Reasons To Convene Advisory Committees
This article was originally published in The Tan Sheet
Executive Summary
Applications for Rx-to-OTC switches will continue to be reviewed in advisory committee meetings because they often meet FDA's reasons to seek an advisory panel's recommendation under a proposed guidance